ATE368649T1 - Cyanoguanidin prodrugs - Google Patents
Cyanoguanidin prodrugsInfo
- Publication number
- ATE368649T1 ATE368649T1 AT03722311T AT03722311T ATE368649T1 AT E368649 T1 ATE368649 T1 AT E368649T1 AT 03722311 T AT03722311 T AT 03722311T AT 03722311 T AT03722311 T AT 03722311T AT E368649 T1 ATE368649 T1 AT E368649T1
- Authority
- AT
- Austria
- Prior art keywords
- sub
- prodrugs
- cyanoguanidine
- cyanoguanidine prodrugs
- cancers
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38083602P | 2002-05-17 | 2002-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE368649T1 true ATE368649T1 (de) | 2007-08-15 |
Family
ID=29550021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03722311T ATE368649T1 (de) | 2002-05-17 | 2003-05-15 | Cyanoguanidin prodrugs |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070249676A1 (de) |
| EP (1) | EP1507760B1 (de) |
| JP (1) | JP4625694B2 (de) |
| KR (1) | KR101010871B1 (de) |
| CN (1) | CN100503570C (de) |
| AT (1) | ATE368649T1 (de) |
| AU (1) | AU2003229534B2 (de) |
| BR (1) | BR0309996A (de) |
| CA (1) | CA2485351C (de) |
| DE (1) | DE60315288T2 (de) |
| ES (1) | ES2290454T3 (de) |
| HK (1) | HK1076812A1 (de) |
| IL (1) | IL165086A (de) |
| IS (1) | IS7562A (de) |
| MX (1) | MXPA04011322A (de) |
| NO (1) | NO330183B1 (de) |
| PL (1) | PL228742B1 (de) |
| RU (1) | RU2326867C2 (de) |
| WO (1) | WO2003097601A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7253193B2 (en) | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
| JP5189367B2 (ja) | 2004-12-22 | 2013-04-24 | レオ ファーマ アクティーゼルスカブ | 新規シアノグアニジン化合物 |
| WO2007022964A2 (de) | 2005-08-24 | 2007-03-01 | Abbott Gmbh & Co. Kg | Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren |
| EP2197443A4 (de) * | 2007-09-26 | 2014-01-01 | Gemin X Pharmaceuticals Canada Inc | Zusammensetzungen und verfahren zur herbeiführung von nad+-spiegeln mithilfe eines nicotinamid-phosphoribosyl-transferase-hemmers |
| EP2342181A1 (de) | 2008-08-29 | 2011-07-13 | Topo Target A/S | Neue harnstoff- und thioharnstoffderivate |
| AU2010210248B2 (en) | 2009-02-06 | 2012-08-16 | Tianjin Hemay Bio-Tech Co., Ltd. | Pharmaceutical compositions comprising pyridyl cyanoguanidine, process for preparing the same and use thereof |
| JP2012533530A (ja) | 2009-07-17 | 2012-12-27 | トポターゲット・アクティーゼルスカブ | ニコチンアミドホスホリボシルトランスフェラーゼ阻害剤による癌治療の副作用の重症度を低下させるためのニコチン酸またはその前駆体もしくはプロドラッグ投与の有効性を予測するための方法 |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
| US9359376B2 (en) * | 2011-04-08 | 2016-06-07 | Sphaera Pharma Pte. Ltd | Substituted methylformyl reagents and method of using same to modify physicochemical and/or pharmacokinetic properties of compounds |
| BR112014032917A2 (pt) * | 2012-06-27 | 2017-06-27 | Alzheimers Inst Of America Inc | compostos e usos terapêuticos dos mesmos |
| CN116640238B (zh) * | 2023-05-30 | 2024-05-03 | 华侨大学 | 一种胍基吡啶壳聚糖鎓盐及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5919816A (en) * | 1994-11-14 | 1999-07-06 | Bionumerik Pharmaceuticals, Inc. | Formulations and methods of reducing toxicity of antineoplastic agents |
| GB9711125D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
| AU4076500A (en) * | 1999-04-09 | 2000-11-14 | Shionogi Bioresearch Corp. | (n)-substituted cyanoguanidine compounds |
| AU1494702A (en) * | 2000-11-21 | 2002-06-03 | Leo Pharma As | Cyanoguanidine prodrugs |
| US20030045515A1 (en) * | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
| BR0309988A (pt) * | 2002-05-17 | 2005-02-22 | Leo Pharma As | Composto, composição farmacêutica, métodos para tratar ou melhorar doenças ou condições proliferativas e doenças inflamatórias, e, uso de um composto |
-
2003
- 2003-05-15 CA CA2485351A patent/CA2485351C/en not_active Expired - Lifetime
- 2003-05-15 RU RU2004136991/04A patent/RU2326867C2/ru active
- 2003-05-15 DE DE60315288T patent/DE60315288T2/de not_active Expired - Lifetime
- 2003-05-15 KR KR1020047018603A patent/KR101010871B1/ko active IP Right Grant
- 2003-05-15 WO PCT/DK2003/000318 patent/WO2003097601A1/en active IP Right Grant
- 2003-05-15 AU AU2003229534A patent/AU2003229534B2/en not_active Ceased
- 2003-05-15 CN CNB038140772A patent/CN100503570C/zh not_active Expired - Fee Related
- 2003-05-15 EP EP03722311A patent/EP1507760B1/de not_active Expired - Lifetime
- 2003-05-15 AT AT03722311T patent/ATE368649T1/de not_active IP Right Cessation
- 2003-05-15 ES ES03722311T patent/ES2290454T3/es not_active Expired - Lifetime
- 2003-05-15 PL PL372769A patent/PL228742B1/pl unknown
- 2003-05-15 MX MXPA04011322A patent/MXPA04011322A/es active IP Right Grant
- 2003-05-15 BR BR0309996-2A patent/BR0309996A/pt not_active Application Discontinuation
- 2003-05-15 JP JP2004505334A patent/JP4625694B2/ja not_active Expired - Fee Related
-
2004
- 2004-11-08 IL IL165086A patent/IL165086A/en active IP Right Grant
- 2004-11-29 IS IS7562A patent/IS7562A/is unknown
- 2004-12-08 NO NO20045374A patent/NO330183B1/no not_active IP Right Cessation
-
2005
- 2005-10-10 HK HK05108938.3A patent/HK1076812A1/xx not_active IP Right Cessation
-
2007
- 2007-06-28 US US11/823,571 patent/US20070249676A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4625694B2 (ja) | 2011-02-02 |
| NO20045374L (no) | 2004-12-08 |
| HK1076812A1 (en) | 2006-01-27 |
| EP1507760B1 (de) | 2007-08-01 |
| AU2003229534A1 (en) | 2003-12-02 |
| EP1507760A1 (de) | 2005-02-23 |
| RU2326867C2 (ru) | 2008-06-20 |
| US20070249676A1 (en) | 2007-10-25 |
| CN1662501A (zh) | 2005-08-31 |
| CA2485351A1 (en) | 2003-11-27 |
| DE60315288D1 (de) | 2007-09-13 |
| IL165086A0 (en) | 2005-12-18 |
| CA2485351C (en) | 2011-12-06 |
| AU2003229534B2 (en) | 2009-08-27 |
| KR101010871B1 (ko) | 2011-01-26 |
| PL228742B1 (pl) | 2018-05-30 |
| MXPA04011322A (es) | 2005-02-17 |
| PL372769A1 (en) | 2005-08-08 |
| DE60315288T2 (de) | 2008-04-10 |
| RU2004136991A (ru) | 2005-06-10 |
| IL165086A (en) | 2011-11-30 |
| BR0309996A (pt) | 2005-02-22 |
| ES2290454T3 (es) | 2008-02-16 |
| IS7562A (is) | 2004-11-29 |
| JP2005538949A (ja) | 2005-12-22 |
| WO2003097601A1 (en) | 2003-11-27 |
| CN100503570C (zh) | 2009-06-24 |
| NO330183B1 (no) | 2011-02-28 |
| KR20050016412A (ko) | 2005-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1076812A1 (en) | Cyanoguanidine prodrugs | |
| CY1118480T1 (el) | Παραγωγα toy uk-2a | |
| PA8571001A1 (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
| ATE461217T1 (de) | Glp-1-verbindungen | |
| ATE408601T1 (de) | Fredericamycin-derivate | |
| UA103873C2 (ru) | Гетероарильные производные мочевины как ингибиторы р38 и их применение | |
| ATE302775T1 (de) | Carbolinderivate | |
| CY1107815T1 (el) | 1,3 - διϋποκατεστημεναι και 1,3,3 -τριϋποκατεστημεναι πυρρολιδιναι ως συνδεσμικα μεσα υποδοχεως ισταμινης -3, και θεραπευτικαι εφαρμογαι των | |
| PT1244650E (pt) | Derivados arilaminas e sua aplicacao como agentes anti-telomerase | |
| AR027355A1 (es) | Acidos tiazolidincarboxilicos | |
| ATE346067T1 (de) | Carbolinderivate | |
| PT1390371E (pt) | Oxazolo- e furopirimidinas e sua utilizacao em medicamentos contra tumores | |
| PE20030061A1 (es) | 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4 | |
| ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| SE0003476D0 (sv) | Compounds | |
| SE0203303D0 (sv) | Novel Compounds | |
| NO20045373L (no) | Cyanoguanidinprodroger | |
| MY139228A (en) | Imidazolinylmethyl aralkylsulfonamides | |
| GB0103240D0 (en) | Organic compounds | |
| UY27587A1 (es) | Heterociclos terapéuticos | |
| UY26498A1 (es) | Pirroles sustituidos | |
| SE0004827D0 (sv) | Therapeutic compounds | |
| DE602004009313D1 (de) | Organosiliziumverbindungen und deren verwendung | |
| ATE293107T1 (de) | Luminacine analoge und deren verwendung | |
| CY1115806T1 (el) | Παραγωγα του κυκλικου eστερα uk-2a χρησιμα στην προληψη ή την αντιμετωπιση μυκητολογικων ασθενειων |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |